HIV/AIDS non-infected pre exposure prophylaxis - HPTN083

Study Information

Status: Active, Not Recruiting

Study Details

View study details on clinicaltrials.gov.

Locations

East Bay

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Description

This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).

Principal Investigator

Jeffrey H. Burack, MD

Recruitment Information

Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at (510) 204-5571.

The Sutter Health Network of Care

Expertise to fit your needs

Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.